# PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogeneic Hematopoietic Transplantation

> **NCT00866346** · PHASE1 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Chronic Myelogenous Leukemia

## Interventions

- **BIOLOGICAL:** PR1-primed lymphocyte (PR1-CTL) Infusion

## Key facts

- **NCT ID:** NCT00866346
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-03
- **Primary completion:** 2015-03
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study failed to accrue any patients due to regulatory issues with PR1 vaccine and T cell production.
- **Last updated:** 2014-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00866346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00866346, "PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogeneic Hematopoietic Transplantation". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00866346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*